MedTrace Logo

Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

NCT03173417 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 177

Last updated 2019-05-20

No results posted yet for this study

Summary

Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia.

Conditions

Interventions

BIOLOGICAL

IM19 CAR-T

T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

DRUG

fludarabine and cyclophosphamide

Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days

Sponsors & Collaborators

  • Beijing Immunochina Medical Science & Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • PEIHUA LU, MD · Hebei Yanda Ludaopei Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-23
Primary Completion
2019-05-01
Completion
2019-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03173417 on ClinicalTrials.gov